Literature DB >> 6760935

Treatment failure in AML.

H D Preisler.   

Abstract

Emphasis on the reasons for successful therapy in the treatment of acute myelocytic leukemia (AML) has generally obscured the problem of treatment failures. This paper discusses failures in remission induction and relapse of leukemia. The contribution of patient-related factors as well as the heterogeneous characteristics of the leukemic cells are considered.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6760935

Source DB:  PubMed          Journal:  Blood Cells        ISSN： 0340-4684


  5 in total

1.  Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia.

Authors:  H D Preisler; T Gessner; N Azarnia; W Bolanowska; J Epstein; A P Early; P D'Arrigo; R Vogler; L Winton; P Chervenik
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Potential limitations of in vitro clonogenic drug sensitivity assays.

Authors:  G W Dong; H D Preisler; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.

Authors:  H Y Chan; F J Meyers; J P Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.

Authors:  R Ganapathi; P Gulick; R Miller; D Grabowski; R Turinic; R Valeunzuela; A Fishleder; R Bukowski
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Development of drug resistance in a murine mammary tumour.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.